Европска Унија - Фински - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - immunoseerumit ja immunoglobuliinit, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Европска Унија - Фински - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiset aineet - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Финска - Фински - Fimea (Suomen lääkevirasto)

astrazeneca oy - primidonum - tabletti - 250 mg - primidoni

Финска - Фински - Fimea (Suomen lääkevirasto)

astrazeneca oy - prilocaini hydrochloridum - injektioneste, liuos - 10 mg/ml - prilokaiini

Финска - Фински - Fimea (Suomen lääkevirasto)

astrazeneca oy - lidocainum - voide - 5 % - lidokaiini

Финска - Фински - Fimea (Suomen lääkevirasto)

astrazeneca oy - lidocaini hydrochloridum - kurlausvesi - 5 mg/ml - lidokaiini

Финска - Фински - Fimea (Suomen lääkevirasto)

astrazeneca uk limited - griseofulvinum - tabletti - 125 mg - griseofulviini

Финска - Фински - Fimea (Suomen lääkevirasto)

astrazeneca uk limited - dapsonum - tabletti - 100 mg - dapsoni

Финска - Фински - Fimea (Suomen lääkevirasto)

astrazeneca oy - cloxacillinum natricum - injektio/infuusiokuiva-aine, liuosta varten - kloksasilliini

Финска - Фински - Fimea (Suomen lääkevirasto)

astrazeneca uk limited - propranololi hydrochloridum - injektioneste - 1 mg/ml - propranololi